Fate Therapeutics earnings were -$175.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest FATE earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$37.6M, down 27.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, FATE reported annual earnings of -$186.3M, with 15.7% growth.
What were Fate Therapeutics's earnings last quarter?
On FATE's earnings call on Invalid Date, Fate Therapeutics (NASDAQ: FATE) reported Q1 2025 earnings per share (EPS) of -$0.32, up 31.91% year over year. Total FATE earnings for the quarter were -$37.62 million. In the same quarter last year, Fate Therapeutics's earnings per share (EPS) was -$0.47.
As of the last Fate Therapeutics earnings report, Fate Therapeutics is currently losing money. Fate Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$175.88 million, a 7.46% decrease year over year.
What was FATE's earnings growth in the past year?
As of Fate Therapeutics's earnings date in Invalid Date, Fate Therapeutics's earnings has grown year over year. FATE earnings in the past year totalled -$175.88 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.